Plasmid News and Research

RSS
NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Vical second-quarter revenues decrease to $2.1 million

Vical second-quarter revenues decrease to $2.1 million

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

International team obtains genome sequence of human body louse

International team obtains genome sequence of human body louse

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Scientific American publishes article on "rebirth" of DNA vaccines

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS